Roche/Prothena License, Development & Commercialisation agreement for anti-alpha-synuclein mAbs (prasinezumab); $30M upfront + up to $600M milestones + US profit share + ex-US royalties.
Did it work? Outcome assessment
Strategic verdict
Too Early
Financial impact
Neutral
Pipeline outcome
Assets Advanced
Assessment window: 5yr post-close.
Key facts
AnnouncedDec 11, 2013
ClosedDec 11, 2013
Deal value$630M
Deal typeLicensing/Option
Therapeutic areaParkinson's disease (and related synucleinopathies)
IndicationsParkinson's disease (and related synucleinopathies)
Key assetsPrasinezumab (PRX002) and PRX003 (anti-alpha-synuclein mAbs)